论文部分内容阅读
研究肝细胞癌 MDR1基因产物 P-gp 的表达及临床意义。方法:应用免疫组化结合图像分析定量测定47例肝癌组织和33例癌旁组织 P-gp 含量,并与肝癌生物学特性比较。结果:肝癌组织和癌旁组织均有 P-gp 表达,且主要位于肝细胞膜上。肝癌组织和癌旁组织 P-gp 含量均高于正常肝组织(P<0.01)。高分化肝癌和肝内复发肝癌 P-gp 含量分别高于低分化肝癌和未复发肝癌(P<0.01),侵袭性肝癌 P-gp 含量也高于非侵袭性肝癌(P<0.05)。结论:P-gp 表达可能成为肝癌预后判断的生物学指标。
To study the expression and clinical significance of P-gp in MDR1 gene product in hepatocellular carcinoma. METHODS: Immunohistochemistry and image analysis were used to quantify the P-gp content in 47 cases of hepatocellular carcinoma and 33 cases of paracancerous tissues, and compared with the biological characteristics of hepatocellular carcinoma. RESULTS: P-gp was expressed in both HCC tissues and paracancerous tissues, and was mainly located on the hepatocyte membrane. The content of P-gp in hepatocellular carcinoma tissues and adjacent tissues was higher than that in normal liver tissues (P<0.01). The P-gp levels in well-differentiated liver cancer and intrahepatic recurrent hepatocellular carcinoma were higher than those in poorly differentiated liver cancer and non-recurrent liver cancer (P<0.01). The invasive liver cancer P-gp content was also higher than that in non-invasive liver cancer (P<0.05). Conclusion: P-gp expression may be a biological indicator of prognosis of HCC.